Clinical Trial Datasets
ACTG 364 clinical trial
References
Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA;
AIDS Clinical Trials Group 364 Study Team., Nelfinavir, efavirenz, or both after the failure of nucleoside
treatment of HIV infection. N Engl J Med. 2001 Aug 9;345(6):398-407.
Bosch RJ, Downey GF, Katzenstein DA, Hellmann N, Bacheler L, Albrecht MA; ACTG 364 Study Team, Evaluation
of cutpoints for phenotypic hypersusceptibility to efavirenz. AIDS. 2003 Nov 7;17(16):2395-6.
Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA; ACTG 364 Study Team, Phenotypic
susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral
drugs. AIDS. 2003 Apr 11;17(6):821-30.
Sequences
Nucleotide sequences in fasta format
ACTG364_PR_fasta.txt, ACTG364_RT_fasta.txt Composite alignment (of sequences at baseline) ACTG364_PR_composite.html, ACTG364_RT_composite.html List of sequences with stop codon, ambiguity codon and unusual residues ACTG364_PR_QA.txt, ACTG364_RT_QA.txt
Method: Direct PCR, Dideoxy terminator sequencing Browse
Integrated view of ARV, genotypes, RNA and CD4 on 159 patients
Complete Dataset
The Microsoft Access database ACTG364Summary.mdb was created on 159 patients for whom sequences are available and contains tables with treatment, mutations, RNA levels and CD4 counts.
The files contained ACTG364Summary.mdb (the description of each file)
|